KALINOR effervescent tablets, 90 pcs

Active substance: potassium citrate.

Composition: The active substance is present in the effervescent tablet as potassium citrate, potassium hydrogen carbonate and citric acid after conversion: 2.17 g potassium citrate (Ph.Eur.) 2.00 g potassium hydrogen carbonate 2.057 g citric acid. Excipients with known effect: 1.42 g glucose syrup and sucrose. Note for diabetics: 1 effervescent tablet corresponds to 0.12 bread units (BE).

Areas of application: Kalinor effervescent tablets are used in adults. For potassium substitution in: pronounced hypokalemia (
Contraindications: Hypersensitivity to potassium citrate, potassium bicarbonate, citric acid or any of the excipients. Kalinor effervescent tablets must not be used in diseases that are often associated with hyperkalemia: dehydration, restricted excretory kidney function, Addison’s disease, adynamia episodica hereditaria.

Side effects: Occasionally: heartburn, abdominal pain, diarrhea, belching, nausea/vomiting, flatulence. Rare: hyperkalemia; Allergic reactions such as: eczema, itching, rash, facial swelling. In this case, the drug should be discontinued. Very rare: Excessive intake of potassium can lead to cardiac arrhythmias.
Detailed instructions for KALINOR effervescent tablets, 15 pcs
field of use
The ready-to-drink solution of the preparation contains the active substance potassium citrate (40.0 mmol potassium ions, corresponding to 1.56 g potassium and at least 13.3 mmol citrate ions, corresponding to 2.5 g citrate). The active substance is present in the effervescent tablet as potassium citrate, potassium bicarbonate and citric acid after conversion.
This medicine is a mineral-potassium supplement used to normalize potassium levels and prevent kidney stones.
To replace potassium (potassium substitution) in:
Pronounced decrease in the blood potassium concentration (hypokalemia < 3.2 mmol/l), especially in the case of concomitant metabolic hyperacidity of the blood (metabolic acidosis), Potassium deficiency disorders of nerve and muscle activity (hypokalaemic neuromuscular disorders) or cardiac arrhythmias, Lowering of the blood potassium concentration (hypokalemia) with simultaneous treatment with heart medication containing digitalis. To avoid a decrease in blood potassium concentration (hypokalemia) in: Acidification of the blood by ketone bodies (ketoacidosis), e.g. in diabetes. To prevent the formation of new kidney stones (kidney stone metaphylaxis) in: Calcium stones (e.g. when the renal tubules are unable to excrete sufficient amounts of hydrogen ions, ie in renal tubular acidosis), Insufficient citrate excretion (hypocitraturia < 320 mg/d of various origins), uric acid stones. If you do not feel better or if you feel worse after 3 days, contact your doctor. Hints For risks and side effects, read the leaflet and ask your doctor or pharmacist. Kalinor effervescent tablets (pack size: 15 pieces) are only available from pharmacies and can be purchased from your mail-order pharmacy apodiscounter. Miscellaneous - Before use, blood salts, heart rhythm and kidney function should be checked. - If pronounced nausea, severe vomiting, severe abdominal pain or flatulence, diarrhea and gastrointestinal bleeding occur during treatment with potassium supplements, the drug should be discontinued immediately, as these symptoms may indicate an ulcer or a perforation in the digestive tract.